Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL133032 | 1.00 | SIRT2 (0.53) | SIRT2SIRT1SLC1A3SLC1A1CTSL | |
| SCHEMBL3902571 | 1.00 | SIRT2 (0.53) | SIRT2SIRT1SLC1A3SLC1A1CTSL | |
| SCHEMBL8054994 | 0.99 | SIRT2 (0.55) | SIRT2SIRT1SLC1A3SLC1A1CTSL | |
| SCHEMBL3319289 | 0.96 | CTSL (0.56) | SIRT2SIRT1SLC1A3SLC1A1CTSL | |
| SCHEMBL1734009 | 0.96 | CTSL (0.56) | SIRT2SIRT1SLC1A3SLC1A1CTSL | |
| SCHEMBL22648528 | 0.91 | SLC1A3 (0.56) | SIRT2SIRT1SLC1A3SLC1A1CTSL | |
| SCHEMBL1596691 | 0.89 | CTSL (0.52) | SIRT2SIRT1CTSLCTSSSYK | |
| SCHEMBL4542544 | 0.86 | SMN1; SMN2 (0.54) | SIRT2SIRT1CTSLCTSSSYK | |
| SCHEMBL130760 | 0.85 | MEN1 (0.51) | SIRT2SIRT1CTSLCTSSSYK | |
| SCHEMBL17865359 | 0.84 | SLC1A3 (0.55) | SLC1A3SLC1A1CTSLCTSSSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069373-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100056501-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100048541-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
| US-7655647-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20100009966-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090170831-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-07-02 | — | — | US | disclosed |
| US-7498324-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080221087-A1 | Substituted lactams as inhibitors of abeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-09-11 | — | — | US | disclosed |
| US-7390802-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-06-24 | — | — | US | disclosed |
| US-7276495-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070173491-A1 | Substituted lactams as inhibitors of Abeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221087-A1 | Substituted lactams as inhibitors of abeta protein production | BACE1, APP, APH1A | SIRT2 3483/4885SIRT1 2681/4885SLC1A3 801/4885 |
| US-20100009966-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | SIRT2 3483/4885SIRT1 2681/4885SLC1A3 801/4885 |
| US-20100048541-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | SIRT2 3483/4885SIRT1 2681/4885SLC1A3 801/4885 |
| US-20090170831-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | SIRT2 3408/4885SIRT1 2566/4885SLC1A3 864/4885 |
| US-20070173491-A1 | Substituted lactams as inhibitors of Abeta protein production | BACE1, APP, APH1A | SIRT2 3483/4885SIRT1 2681/4885SLC1A3 801/4885 |
| US-20100069373-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BACE1, APP, BACE2 | SIRT2 3094/4885SIRT1 2269/4885SLC1A3 1088/4885 |
| US-20100056501-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | SIRT2 3483/4885SIRT1 2681/4885SLC1A3 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.